Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of BT051 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of BT051 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADS 051 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Sponsors Bacainn Therapeutics

    • Most Recent Events

    • 06 Mar 2025 According to an Adiso Therapeutics media release, ADS051 data generated from two Phase 1 studies(Single Ascending Dose Study and Multiple Ascending Dose Study) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) within an end-of-Phase 1 meeting.
    • 06 Mar 2025 According to an Adiso Therapeutics media release, results from this study has been published in the American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG).
    • 06 Mar 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top